Please login to the form below

Not currently logged in

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

Takeda UK & Ireland Peter Wheatley PriceTakeda UK & Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm's new US-based global pricing, market access and health economics oncology division.

Wheatley Price joins Takeda from GlaxoSmithKline, where he served as global market access and pricing director from 2014 to January this year, during which time he oversaw the launch of the company's first respiratory biologic for severe asthma.

Prior to this, Wheatley Price was associate director of health economics market access and reimbursement for oncology across Europe, the Middle East and Africa at Janssen, having joined as interim head of outcomes research in 2010.

He also brings experience form Boehringer Ingelheim, where he was director of its UK Change Project, head of UK market access for prescription medicines, and held a series of marketing management positions.

Adam Zaeske, managing director of Takeda UK, said: “Owing to our ambitions to continue to deliver improved outcomes both for patients and our customers, I am delighted that we have been able to attract such a strong talent as Peter to take on such an important role in our organisation.

“It is clear to me that he shares our vision for Takeda and has both the experience and passion to help us to grow the business.”

27th January 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...